全球臍帶血·臍帶組織銀行產業:市場規模，分類，預測 (2024年)

EXECUTIVE SUMMARY

The first transplant using cord blood-derived hematopoietic stem cells (HSCs) occurred in October 1988. Since then, significant advancements have been made in researching umbilical cord blood-derived hematopoietic and progenitor cells. To date, over 40,000 umbilical cord blood transplants (UCBTs) have been performed worldwide, treating a variety of conditions, including hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. Public cord blood banks now store more than 800,000 units, while private banks house over 8.1 million units globally.

Cord blood storage began as a commercial service in the early 1990s, but cord tissue storage only became available commercially in 2008, with HealthBanks Biotech Company Ltd. in Taiwan leading the way. Hong Kong's HealthBaby and Cryolife also introduced the service in 2009. In the U.S., Cord Blood Registry (CBR) was the first private company to offer cord tissue storage in July 2010. Today, nearly all U.S. cord blood banks and about one-third of global cord blood banks provide cord tissue storage.

LifebankUSA pioneered placental blood storage in the U.S. in 2006 and introduced placental tissue storage in 2011. Americord Registry followed with placental tissue banking in September 2017. Internationally, several cord blood banks now offer placental blood and tissue storage. Some have diversified into other stem cell sources, such as dental pulp stem cells. For example, DentCell, managed by Cryoholdco, Latin America's largest cord blood banking consolidator, focuses on dental pulp stem cells. Additionally, a few cord blood banks are expanding into adipose-derived stem cell storage.

Recent years have seen record levels of merger and acquisition (M&A) activity in the cord blood industry. The market is now predominantly controlled by a handful of large cord blood banking operators, including Global Cord Blood Corporation (GCBC), Cord Blood Registry (owned by CooperSurgical), ViaCord, Cryo-Cell International, Cordlife Group, VCANBIO Cell & Gene Engineering Corporation, Lifecell International, Cryoholdco, and Medipost. This consolidation is notable given the rapid growth of the industry in the early 2000s. Significant consolidation has occurred in the U.S., Europe, Asia, and Latin America:

• PBK FamiCord has acquired most of the European market, including merging with it largest competitor Vita34 and acquiring assets from Cryo-Save AG's 2019 bankruptcy.
• CooperSurgical has consolidated reproductive, newborn stem cell, and genetic services within the U.S., managing at least 1.1 million units.
• Cryoholdco has amassed stem cell banking assets across Latin America, including four in Mexico, two in Colombia, two in Brazil, and one in Peru, totaling an estimated 300,000 units.
• Sanpower Group dominates the Asian market through its ownership of Global Cord Blood Corporation and other assets across Southeast Asia, controlling over 1.2 million units.
• India, with its burgeoning population of 1.4 billion, rivals China in size, making up approximately 36% of the world's 7.8 billion people. LifeCell International is the leading stem cell bank in India, storing over 320,000 units.

The cord blood industry has also seen substantial advancements in perinatal tissue applications, including umbilical cord blood, umbilical cord tissue, placental blood and tissue, and amniotic fluid. This has led to a proliferation of storage services for these biomaterials.

Many cord blood banks have expanded their offerings to include:

• Reproductive and assisted fertility services
• Pre-and post-natal genetic testing
• Cell therapy product development

The Cord Blood and Tissue Market is composed of several segments, including:

• 1. Storage (Cryopreservation): Revenue comes from cord blood collection, processing, and long-term storage contracts. Investment firms have recently entered this market, acquiring stakes in cord blood and tissue banks.
• 2. Transplantation Medicine: There is a robust market for cord blood use in treating diseases such as leukemia and sickle cell disease. Over 40,000 UCB transplants have been performed, with more than 80 medical conditions approved for treatment with cord blood-derived stem cells.
• 3. Regenerative Medicine: Research into the use of cord blood and tissue in regenerative medicine is expanding. Clinical trials are exploring treatments for neurological disorders like cerebral palsy, autism spectrum disorder, and hearing loss. RheinCell Therapeutics, now owned by Catalent, has achieved GMP certification for manufacturing cord blood-derived iPSCs. The FDA approved the world's first expanded cord blood cell therapy, Omisirge, in April 2023.
• 4. Research Supply Products: This segment includes cells, tissues, reagents, and kits. Major market leaders such as Lonza, STEMCELL Technologies, and AllCells are now offering cord blood products for research purposes.

This report provides a comprehensive analysis, including:

• 1. The number of cord blood and tissue units cryopreserved in public and private banks worldwide.
• 2. The number of hematopoietic stem cell transplants performed globally using cord blood cells.
• 3. The use of cord blood cells in regenerative medicine clinical trials.
• 4. The decline in cord blood utilization for HSCT since 2005.
• 5. Emerging technologies influencing public cord blood banks' financial sustainability.
• 6. Future prospects for companion products derived from cord blood.
• 7. The evolving landscape of the cord blood and tissue banking market.
• 8. Expansion and extension of services by cord blood banks.
• 9. Economic models and cost analyses for public and private cord blood banks.
• 10. Profit margins and pricing for processing and storage in private banks.
• 11. Rates per cord blood unit in the U.S. and Europe.
• 12. Indications for cord blood-derived HSCs in transplantation medicine.
• 13. Diseases targeted by cord blood-derived MSCs in regenerative medicine.
• 14. Cord blood processing technologies and the dominant market leaders offering them.
• 15. Clinical trials, published scientific papers, and funding for cord blood research.
• 16. Patents for cord blood, cord tissue, and placental products.
• 17. Transplantation data from various cord blood registries.

Key questions addressed in this market report include:

• 1. Strategies to improve the financial stability of private cord blood banks.
• 2. Strategies to improve the financial stability of public cord blood banks.
• 3. Companion products being developed from cord blood and tissue.
• 4. Costs for processing and storing cord blood.
• 5. Market value of cryopreserved cord blood units upon release.
• 6. Financial losses commonly incurred by public cord blood banks.
• 7. Net profit margins for private cord blood banks.
• 8. Pricing for processing and storage services in private banks.
• 9. Rates per cord blood unit in the U.S. and Europe.
• 10. Revenues from cord blood sales for major banks.
• 11. Accreditation systems for cord blood and tissue banks.
• 12. Comparative merits of cord blood processing technologies.
• 13. Strategies to increase cord blood utilization in transplantation.
• 14. Preferred TNC counts for transplantation.
• 15. Number of registered clinical trials using cord blood and cord tissue.
• 16. Clinical trials studying ex vivo expansion of cord blood and a recent product approval.
• 17. Annual number of matching and mismatching cord blood transplantations.
• 18. Share of cord blood transplants compared to bone marrow and peripheral blood transplants.
• 19. Likelihood of finding matching allogeneic cord blood units by ethnicity.
• 20. Top countries for cord blood donations.
• 21. Diseases targeted by cord blood and tissue-derived MSCs in clinical trials.
• 22. Breakdown of clinical trials investigating cord blood-derived cells by geography, study type, phase, and funding.
• 23. Breakdown of trials exploring cord tissue-derived cells.
• 24. Current patent rates and leading jurisdictions for cord blood, cord tissue, and placental patents.
• 25. Leading inventors, applicants, and owners of perinatal stem cell patents.
• 26. Number of units stored by public and private banks worldwide.
• 27. Leading cord blood banks by region and storage volume.
• 28. Market sizes for cord blood and tissue banking and therapeutic applications.

This global strategic report offers a thorough analysis of the cord blood and tissue banking market, providing insights into current trends, future projections, and key players in the industry. It is an essential resource for those seeking a comprehensive understanding of the market without investing excessive time in research.

TABLE OF CONTENTS

1. REPORT OVERVIEW

• 1.1. Statement of the Report
• 1.2. Executive Summary
• 1.3. Introduction

2. CORD BLOOD BANKS: AN OVERVIEW

• 2.1. Components of a Cord Blood Sample
• 2.2. Cord Blood Banks
  • 2.2.1. Public Cord Blood Bank
    • 2.2.1.1. Public Cord Blood Banks in the U.S.
    • 2.2.1.2. Public Cord Blood Banks in Major European Countries
    • 2.2.1.3. Economic Model of Public Cord Blood Banks
    • 2.2.1.4. Cost Analysis for Public Cord Blood Banks
    • 2.2.1.5. Relationship between Costs and Release Rates
  • 2.2.2. Private Cord Blood Banks
    • 2.2.2.1. Private Cord Blood Banks in the U.S
    • 2.2.2.2. Top Seven U.S. Private Cord Blood Banks by Size of Inventory
    • 2.2.2.3. Comparison of Top Three U.S. Private Cord Blood Banks
    • 2.2.2.4. Pricing for Processing and Storage of CB in Private Banks
    • 2.2.2.5. Major U.S. Private Cord Blood Banks by their Special Services
    • 2.2.2.6. Key Factors to be Considered by Parents before Choosing a Private Bank
    • 2.2.2.7. World's Top Ten Private Cord Blood Banks by Inventory
    • 2.2.2.8. Special Features of World's Largest Private Cord Blood Banks
    • 2.2.2.9. Cost Analysis for Private Cord Blood Banks
      • 2.2.2.9.1. Economic Model of Private Cord Blood Banks
      • 2.2.2.9.2. Profit Margins of Four Global Private Cord Blood Banks
  • 2.2.3. Hybrid Cord Blood Banks
  • 2.2.4. Cross-over Cord Blood Bank
  • 2.2.5. Community Cord Blood Bank
• 2.3. Proportion of Public, Private and Hybrid Cord Blood Banks in the U.S.

3. CORD BLOOD BANK ACCREDITATIONS

• 3.1. American Association of Blood Banks (AABB)
  • 3.1.1. AABB Accreditation Phases and Expectations
• 3.2. Foundation for the Accreditation of Cellular Therapy (FACT)
  • 3.2.1. FACT Standards
  • 3.2.2. FACT Accreditation Process
• 3.3. FDA Registration of Cord Blood Banks
  • 3.3.1. FDA Biologics License Application (BLA) for Cord Blood
  • 3.3.2. Investigation New Drug (IND) for Cord Blood
• 3.4. Human Tissue Authority (HTA) in U.K.
• 3.5. Therapeutic Goods Act (TGA) in Australia
• 3.6. International NetCord Foundation

4. PATENT LANDSCAPE OF UMBILICALCORD BLOOD, CORD TISSUE & PLACENTA

• 4.1. Umbilical Cord Blood Stem Cell Patents
  • 4.1.1. Legal Status of Cord Blood Patents
  • 4.1.2. Umbilical Cord Blood Patent Applications by Year
  • 4.1.3. Umbilical Cord Blood Patent Application by Jurisdiction
  • 4.1.4. Top Ten Umbilical Cord Blood Patent Applicants
  • 4.1.5. Top Ten Inventors of Umbilical Cord Blood Patents
  • 4.1.6. Top Twenty Owners of Umbilical Cord Blood Patents
• 4.2. Patents on Umbilical Cord Blood-Derived MSCs
  • 4.2.1. Legal Status of UCB-Derived MSC Patents
  • 4.2.2. UCB-Derived MSC Patent Applications by Year
  • 4.2.3. UCB-Derived MSC Patent Application by Jurisdiction
  • 4.2.4. Top Ten UCB-Derived MSC Patent Applicants
  • 4.2.5. Top Ten Inventors of UCB-Derived MSC Patents
  • 4.2.6. Top Twenty Owners of UCB-Derived MSC Patents
• 4.3. Patents on Cord Tissue
  • 4.3.1. Legal Status of Cord Tissue Patents
  • 4.3.2. Cord Tissue Patent Applications by Year
  • 4.3.3. Cord Tissue Patent Application by Jurisdiction
  • 4.3.4. Top Ten Cord Tissue Patent Applicants
  • 4.3.5. Top Ten Inventors of Cord Tissue Patents
  • 4.3.6. Top Twenty Owners of Cord Tissue Patents
• 4.4. Patents on Placenta
  • 4.4.1. Leading Placenta-based Patent Applicants
  • 4.4.2. Placental Tissue Patent Applications by Year, 2000-2022
  • 4.4.3. Top Ten Jurisdictions of Placental Tissue Patents
  • 4.4.4. Top Ten Inventors of Placental Tissue Patents
  • 4.4.5. Top Twenty Owners of Placental Tissue Patents
  • 4.4.6. Legal Status of Placental Tissue Patents
• 4.5. Patents on Cord Blood Expansion
  • 4.5.1. Number of Cord Blood Expansion Patent Applications by Year
  • 4.5.2. Top Ten Jurisdictions of CB Expansion Patents
  • 4.5.3. Legal Status of Cord Blood Expansion Patents
  • 4.5.4. Top Ten Inventors of Cord Blood Expansion Patents
  • 4.5.5. Top 20 Owners of Cord Blood Expansion Patents

5. UMBILICAL CORD BLOOD RESEARCH PUBLICATIONS

• 5.1. Number of Papers Published on Umbilical Cord Blood
• 5.2. Scientific Publications on Cord Tissue
• 5.3. Scientific Publications on Placental Tissue
• 5.4. Scientific Publications on UCB Cell Expansion

6. CLINICAL TRIAL: CORD BLOOD, CORD TISSUE, PLACENTA AND CB EXPANSION

• 6.1. Clinical Trials involving Cord Blood Stem Cells
  • 6.1.1. Number of Clinical Trials using Cord Blood Stem Cells by Geography
  • 6.1.2. Number of Cord Blood Clinical Trials by Study Type
  • 6.1.3. Number of Clinical Trials by Phase of Study
  • 6.1.4. Number of Clinical Trials by Funder Type
  • 6.1.5. Diseases Addressed by Currently Recruiting Cord Blood Clinical Trials
  • 6.1.6. Companies Participating in Cord Blood Clinical Trials
• 6.2. Clinical Trials Using Umbilical Cord Tissue
  • 6.2.1. Number of Clinical Trials using Cord Tissue by Region
  • 6.2.2. Number of Umbilical Cord Tissue Clinical Trials by Phase of Study
  • 6.2.3. Number of Cord Tissue Clinical Trials by Funder Type
  • 6.2.4. Commercial Entities in Umbilical Cord Tissue Clinical Trials
• 6.3. Clinical Trials using Placental Tissue Stem Cells
  • 6.3.1. Number of Placental Tissue Clinical Trials by Phase of Study
• 6.4. Clinical Trials of Expanded Cord Blood
  • 6.4.1. Major Participants in Clinical Trials using Expanded Cord Blood Cells

7. CORD BLOOD PROCESSING TECHNOLOGIES: AN OVERVIEW

• 7.1. The Process of Separation of Cord Blood Stem Cells
  • 7.1.1. PrepaCyte CB
    • 7.1.1.1. Advantages of PrepaCyte-CB
    • 7.1.1.2. Treatment Outcomes with PrepaCyte-CB
  • 7.1.2. Hetastarch (HES)
  • 7.1.3. AutoXpress (AXP)
  • 7.1.4. SEPAX
  • 7.1.5. Plasma Depletion Method (MaxCell Process)
  • 7.1.6. Density Gradient Method
• 7.2. Comparative Merits of Different Processing Methods
  • 7.2.1. Early Stage HSC Recovery by Technologies
  • 7.2.2. Mid Stage HSC (CD34+/CD133+) Recovery from CB by Technologies
  • 7.2.3. Late Stage Recovery of HSC from Cord Blood by Technologies
  • 7.2.4. HSC (CD45+) Recovery
• 7.3. Days to Neutrophil Engraftment by Technologies
• 7.4. Anticoagulants used in Cord Blood Processing
  • 7.4.1. Type of Anticoagulant and Cell Recovery Volume
• 7.5. Percent Cell Recovery by Sample Size
• 7.6. TNC Viability by Time Taken for Transport and Type of Anticoagulant
• 7.7. Cryopreservation of Cord Blood Cells
  • 7.7.1. Ideal Cryoprotectants
• 7.8. Bioprocessing of Umbilical Cord Tissue (UCT)
• 7.9. Cord Blood Expansion Technologies
  • 7.9.1. Notch Ligand Delta 1
  • 7.9.2. Co-Culture with MSCs
  • 7.9.3. Copper Chelation
  • 7.9.4. Nicotinamide
  • 7.9.5. StemRegenin 1 (SR1)
  • 7.9.6. UM171
  • 7.9.7. Augmentation of Homing
  • 7.9.8. Prostaglandin E2
  • 7.9.9. Complement 3a (C3a)
  • 7.9.10. Fucosylation

8. CORD BLOOD UNITS AVAILABLE WORLDWIDE: AN OVERVIEW

• 8.1. Number of Allogeneic CBU Donors and CBUs Available Worldwide
• 8.2. HLA Typing of Worldwide Unrelated CB Donors and CBUs in 2021
• 8.3. Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
• 8.4. Global Exchange of Cord HSCs

9. INDICATIONS FOR UMBILICAL CORD BLOOD TRANSPLANTATION

• 9.1. Beneficial Properties of Cord Blood Stem Cells
  • 9.1.1. Hematopoietic Properties of UCBCs
  • 9.1.2. Immune Properties of UCBCs
  • 9.1.3. Impact of HLA mismatch in UCBT Recipients
• 9.2. Malignant Indications for UCB Transplantation
• 9.3. Non-Malignant Diseases Treated by UCB Transplantation
• 9.4. Diseases being Studied using UCB as Regenerative Medicine

10. CORD BLOOD: AS A TRANSPLANT MEDICINE

• 10.1. Numbers of CB, BM and PB Stem Cell Transplantations Compared
• 10.2. Cord Blood Stem Cells Transplantation by Geography, 1999-2021
  • 10.2.1. Indications for Hematopoietic Stem Cell Transplants (HSCTs) in the U.S.
    • 10.2.1.1. Top Five Indications for HCT in the U.S.
    • 10.2.1.2. Trends in Allogeneic HCTs in the U.S., by Recipient Age
    • 10.2.1.3. Trends in the Autologous HCT in the U.S. by Recipient Age
    • 10.2.1.4. HCTs by Cell Source in Adult Patients in the U.S.
    • 10.2.1.5. HCTs by Cell Source in less than 18 Patients in the U.S.
    • 10.2.1.6. Trends in the Use of Cord Blood HCTs in Adult & less than 18 Patients in the U.S.
    • 10.2.1.7. Number of Allogeneic CB HCTs in the U.S. by Race
    • 10.2.1.8. Number of HCTs Performed in the U.S. by Cell Source and Donor Type
    • 10.2.1.9. Use of CB Allogeneic HCTs in the U.S. in Recipients Aged less than 18 Years
    • 10.2.1.10. Use of Allogeneic CB HCTs in the U.S. in Recipients Aged greater than or equal to 18 Years
  • 10.2.2. Ethnic Background and Cord Blood HLA Matching in the U.S.
  • 10.2.3. Cost of Cord Blood Transplantation
  • 10.2.4. Complications through 1-Year Post HCT

11. CORD BLOOD STEM CELLS IN REGENERATIVE MEDICINE

• 11.1. Autism
• 11.2. Cerebral Palsy
• 11.3. Alzheimer's Disease
• 11.4. Diabetes
• 11.5. Heart Diseases
• 11.6. Multiple Sclerosis
• 11.7. Stroke

12. MARKET ANALYSIS

• 12.1. Cord Blood Banking Services Market
  • 12.1.1. Share of Cord Blood Banking Service Market Revenue by Geography
  • 12.1.2. Public vs. Private Cord Blood Banking Service Market
  • 12.1.3. Global Market Share for Cord Blood and Cord Tissue Servicing
• 12.2. Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue
  • 12.2.1. Market Share for CB Transplantation and CB for Regenerative Medicine
  • 12.2.2. Percent Share of Cord Blood & Cord Tissue Market by Indication
• 12.3. Global Market for Umbilical Cord Tissue (UCT)

13. PROFILES OF SELECT CORD BLOOD BANKS & RELATED ORGANIZATIONS

• 13.1. AllCells
  • 13.1.1. Research Use Only (RUO) Products
    • 13.1.1.1. Mobilized Leukopak
    • 13.1.1.2. Leukopak
    • 13.1.1.3. Bone Marrow
    • 13.1.1.4. Cord Blood
    • 13.1.1.5. Whole Blood
  • 13.1.2. GMP Products
    • 13.1.2.1. Clinical Grade Mobilized Leukopak
    • 13.1.2.2. Clinical Grade Leukopak
    • 13.1.2.3. Clinical Grade Bone Marrow
  • 13.1.3. Isolated Cell Products
    • 13.1.3.1. CD34+ HSPCs
    • 13.1.3.2. T Cells
    • 13.1.3.3. NK Cells
    • 13.1.3.4. Monocytes
    • 13.1.3.5. B Cells
    • 13.1.3.6. PBMCs (MNCs)
• 13.2. AlphaCord
  • 13.2.1. Prices
• 13.3. Americord Registry, Inc.
  • 13.3.1. Cord Blood 2.0
  • 13.3.2. Cord Tissue with CryoMax Processing
  • 13.3.3. Placental Tissue with CryoMax processing
• 13.4. Angiocrine Bioscience
  • 13.4.1. Proprietary E-CEL Platform
• 13.5. Anja Health Personalized Cord Blood Banking
• 13.6. Anthony Nolan
  • 13.6.1. Anthony Nolan Grant
• 13.7. Baylx, Inc.
  • 13.7.1. Product Pipeline
• 13.8. Be The Match
  • 13.8.1. Hub of Transplant Network
  • 13.8.2. Partners of Be The Match
  • 13.8.3. Allogeneic Cell Sources in Be The Match Registry
  • 13.8.4. Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
  • 13.8.5. Growth of Cord Blood Units on Be The Match Registry
  • 13.8.6. Diversity of CBUs in Be The Match Registry
• 13.9. Biocell Center
• 13.10. BioEden
  • 13.10.1. Dental Pulp Cells
  • 13.10.2. Differences between Dental Pulp Cells and Cord Blood Cells
• 13.11. BioIntegrate, LLC
• 13.12. Bloodworks Northwest
  • 13.12.1. Products & Services
• 13.13. California Umbilical Cord Collection Program
  • 13.13.1. Participating Locations
• 13.14. Carolinas Cord Blood Bank (CCBB)
• 13.15. Celaid Therapeutics
  • 13.15.1. In Vitro Expansion Technology
  • 13.15.2. Business Model
• 13.16. Celebration Stem Cell Centre (CSCC)
  • 13.16.1. Products
• 13.17. Cell Care
• 13.18. Cellenkos, Inc.
  • 13.18.1. Technology
  • 13.18.2. Cellenkos' Pipeline
• 13.19. Cells4Life Group LLP
  • 13.19.1. Cellsplus
  • 13.19.2. TotiCyte Processing Technology
  • 13.19.3. Cord Blood Releases from Cells4Life
• 13.20. CellSave Arabia
  • 13.20.1. Cord Blood Stem Cell Banking Services
  • 13.20.2. Stem Cell Banking Price
• 13.21. Celularity, Inc.
• 13.22. Center for International Blood and Marrow Transplant Research (CIBMTR)
• 13.23. CHOC Blood Bank
• 13.24. Cleveland Cord Blood Center
  • 13.24.1. Research on Diabetic Retinopathy
  • 13.24.2. Research on Type I Diabetes
  • 13.24.3. Research on Parkinson's disease
  • 13.24.4. Research on Wound Healing
• 13.25. ClinImmune Cell and Gene Therapy
  • 13.25.1. FDA Licensed Cord Blood
  • 13.25.2. Gene Therapy
  • 13.25.3. Cellular Therapies
• 13.26. Cord Blood Bank of Arkansas (CBBA)
• 13.27. Cord Blood Center Group
  • 13.27.1. Cord Blood Units Released form Cord Blood Center Group
• 13.28. Cord Blood Registry (CBR)
  • 13.28.1. Business Experience
  • 13.28.2. Licensing & Accreditation
  • 13.28.3. Pricing
• 13.29. Cord for Life
  • 13.29.1. Technology: PremierMax
• 13.30. CordLife Group, Ltd.
  • 13.30.1. Accreditations & Certifications
  • 13.30.2. Services
  • 13.30.3. Releases from CordLife
  • 13.30.4. Revenue Generation by CordLife Group
• 13.31. CordVida
• 13.32. Crioestaminal
  • 13.32.1. Cord Blood Transplantation in Portugal
• 13.33. Cryo-Cell International, Inc.
  • 13.33.1. Processing Technology
  • 13.33.2. Recovery of Viable CFU by PrepaCyte-CB
  • 13.33.3. Cryo-Cell International's Revenue Generation
  • 13.33.4. Cryo-Cell International's Pricing
• 13.34. CryoCyte, LLC
• 13.35. CryoHoldco LATAM
• 13.36. Cryopoint
• 13.37. Cryoviva Biotech Pvt., Ltd.
• 13.38. DKMS gGMBH
  • 13.38.1. Cord Blood Units
  • 13.38.2. Services
  • 13.38.3. DKMS' Donor Typing Profile & Active Donors
• 13.39. Duke University School of Medicine
  • 13.39.1. Ducord (HPC Cord Blood)
• 13.40. European Society for Blood and Bone Marrow Transplantation (EBMT)
  • 13.40.1. EBMT Transplant Activity
• 13.41. Ever Supreme Bio Technology, Co., Ltd.
  • 13.41.1. Allogeneic UMSC01
  • 13.41.2. New Research
• 13.42. ExCellThera
  • 13.42.1. ECT-001 Cell Therapy
• 13.43. FamiCord Group
• 13.44. Fate Therapeutics, Inc.
  • 13.44.1. FT1050 - Stem Cell Modulator
• 13.45. Future Health
  • 13.45.1. Locations of Laboratories
  • 13.45.2. Business Experience
  • 13.45.3. Collection Kit
  • 13.45.4. Transportation Container
  • 13.45.5. Processing Method
  • 13.45.6. Components Stored
  • 13.45.7. Storage Methods
  • 13.45.8. Licensing & Accreditation
  • 13.45.9. Prices
  • 13.45.10. Additional Services
• 13.46. Gamida Cell
  • 13.46.1. OMIDUBICELL
• 13.47. GeneCell
• 13.48. Global Cord Blood Corporation (GCBC)
  • 13.48.1. GCBC's Revenue Generation
• 13.49. Glycostem Therapeutics
  • 13.49.1. Science and Technology
  • 13.49.2. oNKord
  • 13.49.3. viveNK
  • 13.49.4. uNiK Production Process
• 13.50. Hawaii Cord Blood Bank
• 13.51. HealthBaby
  • 13.51.1. Service Plans
  • 13.51.2. 18-Year Cord Blood (HSCs) Storage Plan
  • 13.51.3. 18-Year CordBasic Umbilical Cord Lining Storage Plan
  • 13.51.4. CellOptima CordPlus Umbilical Cord Lining Storage
• 13.52. HealthBanksUSA
  • 13.52.1. BioArchive Cryogenic Storage System
  • 13.52.2. AXP Cord Blood Processing
• 13.53. HEMAFUND
• 13.54. Hemogenyx Pharmaceuticals
  • 13.54.1. Technology
• 13.55. IMMUNIQUE
• 13.56. Insception LifeBank
  • 13.56.1. Cord Blood Releases from Insception LifeBank
  • 13.56.2. Cord Blood Cells Released for Regenerative Medicine from Insception
• 13.57. JP McCarthy Cord Stem Cell Bank
• 13.58. Kangstem Biotech, Co., Ltd.
  • 13.58.1. GD11 Brand
  • 13.58.2. Core Technology
• 13.59. LifebankUSA
• 13.60. LifeCell International Pvt. Ltd.
• 13.61. Life Line Stem Cell
• 13.62. LifeSouth Cord Blood Bank
  • 13.62.1. Accreditation & Hospital Partners
• 13.63. Magenta Therapeutics
  • 13.63.1. Magenta's Cord Blood-Based Clinical Trial
• 13.64. Maze Cord Blood
• 13.65. Medipost, Co., Ltd.
  • 13.65.1. Medipost's Product & Products in Development
    • 13.65.1.1. CARTISTEM
    • 13.65.1.2. PNEUMOSTEM
    • 13.65.1.3. SMUP-IA-01
• 13.66. Mesoblast, Ltd.
• 13.67. MD Anderson Cord Blood Bank
• 13.68. Mesoblast, Ltd.
  • 13.68.1. Mesoblast's UCB-Based Clinical Trial
• 13.69. MiracleCord, Inc.
  • 13.69.1. AXP II Automated Processing
  • 13.69.2. StemCare Collection Kit
  • 13.69.3. Cost of Cord Blood Banking
• 13.70. Mononuclear Therapeutics, Ltd.
  • 13.70.1. MonoTx Cord Blood Bank
  • 13.70.2. MonoTx's Pipeline
  • 13.70.3. Products
    • 13.70.3.1. Human Cord Blood Mononuclear Cells (MNCs)
    • 13.70.3.2. Exosome Rich Plasma (ERP)
    • 13.70.3.3. Activated Human Cord Blood Platelet-Depleted-Plasma (aPDP)
• 13.71. New England Cord Blood Bank, Inc.
  • 13.71.1. Cord Blood Processing
  • 13.71.2. Cord Blood & Tissue Storage
• 13.72. New York Blood Center
  • 13.72.1. Blood Products & Services
  • 13.72.2. Cell Therapies
  • 13.72.3. Cord Blood
• 13.73. OrganaBio
  • 13.73.1. OrganaBio's Proprietary Supply Chains
  • 13.73.2. Perenatal Tissues
• 13.74. PacifiCord
  • 13.74.1. FDA-Approved Sterile Collection Bags
  • 13.74.2. AXP Processing System
  • 13.74.3. BioArchive System
• 13.75. Plasticell Ltd.
  • 13.75.1. CombiCult Technology
  • 13.75.2. Hematopoietic Stem Cell Expansion
• 13.76. ReeLabs Pvt. Ltd.
• 13.77. Restem, LLC
  • 13.77.1. Clinical Trial for COVID-19
  • 13.77.2. Clinical Trial for Muscular Dystrophy
  • 13.77.3. Clinical Trial for Idiopathic Inflammatory Myositis (IIM)
  • 13.77.4. Clinical Trial for Heart Failure
• 13.78. San Diego Cord Blood Bank
• 13.79. Saneron CCEL Therapeutics, Inc.
  • 13.79.1. U-CORD-CELL Program
  • 13.79.2. SERT-CELL Program
• 13.80. SmartCells
• 13.81. SSM Cardinal Glennon Children's Medical Center
  • 13.81.1. ALLOCORD
• 13.82. Stembanc, Inc.
  • 13.82.1. Popular Packages from Stembanc
• 13.83. Stem Cell Cryobank, Inc.
• 13.84. StemCyte, Inc.
  • 13.84.1. Services
  • 13.84.2. Add On Services
  • 13.84.3. StemCyte in Clinical Trials
  • 13.84.4. StemCyte's Plans & Pricing
• 13.85. Throne Biotechnologies, Inc.
  • 13.85.1. Effects of CB-SCs in Diabetics
  • 13.85.2. Effects of CB-SCs on Alopecia Areata
• 13.86. Transcell Biolife
  • 13.86.1. ScellCare
  • 13.86.2. ToothScell
• 13.87. Upstate Cord Blood Bank
• 13.88. ViaCord
  • 13.88.1. ViaCord's Complete Services
  • 13.88.2. Cord Blood + Tissue Banking
  • 13.88.3. Newborn Digestive Health
  • 13.88.4. Newborn DNA Guardian
• 13.89. Versity, Inc.
• 13.90. Vita 34 AG
  • 13.90.1. Revenue Generation by Vita 34 AG
• 13.91. Vitalant Clinical Services
  • 13.91.1. Hospital Services
  • 13.91.2. Laboratory Services
  • 13.91.3. Research
• 13.92. World Marrow Donor Association (WMDA)
  • 13.92.1. WMDA Search & Match Service
• 13.93. Worldwide Network for Blood & Marrow Transplantation (WBMT)

INDEX OF FIGURES

• FIGURE 2.1: Parts of an Umbilical Cord
• FIGURE 2.2: Percent Utilizations of BM-HSCs, PB-HSCs and CB-HSCs in Transplantations
• FIGURE 2.3: Components of a Cord Blood Sample
• FIGURE 2.4: Top Seven U.S. Private Cord Blood Banks by Size of Inventory
• FIGURE 2.5: Cord Blood Revenues for Four Major Private Banks, 2017 to Present
• FIGURE 2.6: Proportion of Public, Private and Hybrid Cord Blood Banks in the U.S.
• FIGURE 2.7: % Share of Parents Storing CBUs in Private/Public Banks by Country/Region
• FIGURE 4.1: Legal Status of Cord Blood Patents
• FIGURE 4.2: Umbilical Cord Blood Patent Applications by Year, 2000 to Present
• FIGURE 4.3: Umbilical Cord Blood Patent Application by Jurisdiction
• FIGURE 4.4: Legal Status of Cord Blood Patents
• FIGURE 4.5: UCB-Derived MSC Patent Applications by Year, 2000 to Present
• FIGURE 4.6: UCB-Derived MSC Patent Application by Jurisdiction
• FIGURE 4.7: Legal Status of Cord Tissue Patents
• FIGURE 4.8: Umbilical Cord Patent Applications by Year, 2000 to Present
• FIGURE 4.9: Placental Tissue
• FIGURE 4.10: Placental Tissue Patent Applications by Year, 2000 to Present
• FIGURE 4.11: Number of Cord Blood Expansion Patent Applications, 2000 to Present
• FIGURE 5.1: Number of Published Papers on UCB according to PubMed.gov, 2000 to Present..
• FIGURE 5.2: Number of Publications on Umbilical Cord Tissue, 2000 to Present
• FIGURE 5.3: Number of Publications on Placental Tissue
• FIGURE 5.4: Number of Scientific Publications on UCB Cell Expansion, 2000 to Present
• FIGURE 6.1: Number of Cord Blood Clinical Trials by Geography
• FIGURE 6.2: Number of Cord Blood Clinical Trials by Study Type
• FIGURE 6.3: Number of Cord Blood Clinical Trials by Phase of Study
• FIGURE 6.4: Number of Cord Blood Clinical Trials by Funder Type
• FIGURE 6.5: Major Indications Addressed by Currently Recruiting Clinical Trials
• FIGURE 6.6: Number of Clinical Trials using Cord Tissue by Region/Country
• FIGURE 6.7: Number of Cord Tissue Clinical Trials by Phase of Study
• FIGURE 6.8: Number of Cord Blood Clinical Trials by Funder Type
• FIGURE 7.1: Separation of Buffy Layer
• FIGURE 7.2: PrepaCyte-CB
• FIGURE 7.3: Hetastarch (HES)
• FIGURE 7.4: AutoXpress II
• FIGURE 7.5: SEPAX 2
• FIGURE 7.6: Plasma Depletion (PD) Method (MaxCell Process)
• FIGURE 7.7: Density Gradient Separation of Cord Blood
• FIGURE 7.8: Early Stage HSC Recovery from Cord Blood by Technologies
• FIGURE 7.9: Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood by Technologies
• FIGURE 7.10: Late Stage Recovery of HSC from Cord Blood by Technologies
• FIGURE 7.11: HSC (CD45+) Recovery Post Process from CB by Technologies
• FIGURE 7.12: Days to Neutrophil Engraftment by Technologies
• FIGURE 7.13: Differences in TNC Recovery among Anticoagulants
• FIGURE 7.14: Type of Anticoagulant and Cell Recovery Volume
• FIGURE 7.15: Percent Cell Recovery by Sample Size
• FIGURE 7.16: TNC Viability by Time Taken for Transport
• FIGURE 7.17: Difference in Recovery of VIABLE TNC after Thawing
• FIGURE 7.18: CD34+ Cell Count CFU and Cell Apoptosis by Cryoprotectants
• FIGURE 8.1: HLA Typing of Worldwide Unrelated CB Donors and CBUs
• FIGURE 8.2: Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
• FIGURE 8.3: Global Exchange of Cord HSCs
• FIGURE 9.1: Percent Utilization of PB, BM and CB in Transplantations Worldwide
• FIGURE 10.1: CB, BM and PB Stem Cell Transplantations Compared, 1997-2021
• FIGURE 10.2: Cord Blood Stem Cells Transplantation by Geography, 1999 to Present
• FIGURE 10.3: Major Five Indications for HCT in the U.S.
• FIGURE 10.4: Trends in Allogeneic HCTs in the U.S., by Recipient Age
• FIGURE 10.5: Trends in the Autologous HCT in the U.S. by Recipient Age
• FIGURE 10.6: HCTs by Cell Source in Adult Patients in the U.S.
• FIGURE 10.7: HCTs by Cell Source in less than 18 Patients in the U.S.
• FIGURE 10.8: Trends in the Use of CB HCTs in greater than or equal to 18 & less than 18 Patients in the U.S.
• FIGURE 10.9: Number of Allogeneic CB HCTs in the U.S. by Race
• FIGURE 10.10: Use of CB Allogeneic HCTs in the U.S. in Recipients Aged less than 18 Years
• FIGURE 10.11: Use of Allogeneic CB HCTs in the U.S. in Recipients Aged greater than or equal to 18 Years
• FIGURE 12.1: Global Cord Blood Banking Service Market, 2022-2030
• FIGURE 12.2: % Share of Cord Blood Banking Service Market Revenue by Geography
• FIGURE 12.3: Global Cord Blood Banking Service Market, Public vs. Private
• FIGURE 12.4: Global CB Banking Service Market Share for Cord Blood and Cord Tissue
• FIGURE 12.5: Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue, 2022-2030
• FIGURE 12.6: Use of Umbilical Cord Blood in Transplantation vs. Regenerative Medicine
• FIGURE 12.7: Percent Share of Umbilical Cord Blood and Tissue Utilization by Indication
• FIGURE 13.1: Cell Sources for Allogeneic HCT Facilitated by Be The Match Registry
• FIGURE 13.2: Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
• FIGURE 13.3: Growth of CBUs on Be The Match Registry, 2001 to Present
• FIGURE 13.4: Diversity of CBUs in Be The Match Registry
• FIGURE 13.5: Funders for CIBMTR in 2022
• FIGURE 13.6: Sales Revenues and Gross Profits for CordLife, 2014-2021
• FIGURE 13.7: Cryo-Cell International's Revenue Generation, 2017-2022
• FIGURE 13.8: GCBC's Revenue Generation, 2015-2022
• FIGURE 13.9: Revenue Generation by Vita 34 AG, 2014-2021

INDEX OF TABLES

• TABLE 2.1: An Overview of Public Cord Blood Banks
• TABLE 2.2: Public Cord Blood Banks in the U.S.
• TABLE 2.3: Public Cord Blood Banks in Major European Countries
• TABLE 2.4: International Prices of a Cord Blood Unit (CBU)
• TABLE 2.5: Prices of CBUs in National Marrow Donor Program (NMDP) Banks in the U.S.
• TABLE 2.6: An Overview of Private Cord Blood Banks
• TABLE 2.7: The Leading Private Cord Blood Banks in the U.S.
• TABLE 2.9: Pricing for Storage in Commercial Cord Blood Banks
• TABLE 2.10: Leading Private CB Banks by their Inventory Size and Geographic Location
• TABLE 2.11: World's Largest Private Cord Blood Bank Operators by Inventory
• TABLE 2.12: Cord Blood Revenues for Four Major Private Banks - 2017 to Present
• TABLE 2.13: Comparison of Public, Private and Hybrid Cord Blood Banks
• TABLE 3.1: AABB-Accredited Cord Blood Banks
• TABLE 3.2: Select FACT-Accredited Cord Blood Banks
• TABLE 4.1: Umbilical Cord Blood Patent Application by Jurisdiction
• TABLE 4.2: Top Ten Umbilical Cord Blood Patent Applicants
• TABLE 4.3: Top Ten Inventors of Umbilical Cord Blood Patents
• TABLE 4.4: Top Twenty Owners of Umbilical Cord Blood Patents
• TABLE 4.5: UCB-Derived MSC Patent Applications by Jurisdiction
• TABLE 4.6: Top Ten UCB-Derived MSC Patent Applicants
• TABLE 4.7: Top Ten Inventors of UCB-Derived MSC Patents
• TABLE 4.8: Top Twenty Owners of UCB-Derived MSC Patents
• TABLE 4.9: Cord Tissue Patent Application by Jurisdiction
• TABLE 4.10: Top Ten Wharton's Jelly Patent Applicants
• TABLE 4.11: Top Ten Inventors of Cord Tissue Patents
• TABLE 4.12: Top Twenty Owners of Cord Tissue Patents
• TABLE 4.13: Top Ten Applicants of Placental Tissue Patents
• TABLE 4.14: Top Ten Jurisdictions of Placental Tissue Patents
• TABLE 4.15: Top Ten Inventors of Placental Tissue Patents
• TABLE 4.16: Top Twenty Owners of Placental Tissue Patents
• TABLE 4.17: Legal Status of Placental Tissue Patents
• TABLE 4.18: Top Ten Jurisdictions of CB Expansion Patents
• TABLE 4.19: Legal Status of Cord Blood Expansion Patents
• TABLE 4.20: Top Ten Inventors of Cord Blood Expansion Patents
• TABLE 4.21: Top Twenty Owners of Placental Tissue Patents
• TABLE 6.1: Total Number of Umbilical Cord-Related Clinical Studies
• TABLE 6.2: Number of Cord Blood Clinical Trials by Geography
• TABLE 6.3: Number of Cord Blood Clinical Trials by Study Type
• TABLE 6.4: Number of Cord Blood Clinical Trials by Phase of Study
• TABLE 6.5: Number of Cord Blood Clinical Trials by Funder Type
• TABLE 6.6: List of Select Companies Participating in Cord Blood Clinical Trials
• TABLE 6.7: Number of Cord Tissue Clinical Trials by Phase of Study
• TABLE 6.8: Number of Cord Tissue Clinical Trials by Funder Type
• TABLE 6.9: Select Commercial Entities in Umbilical Cord Tissue Clinical Trials
• TABLE 6.10: Number of Placental Tissue Clinical Trials by Phase of Study
• TABLE 6.11: Major Industry Participants using Expanded Cord Blood in Clinical Trials
• TABLE 7.1: Advantages of PrepaCyte-CB
• TABLE 7.2: Treatment Outcomes with PrepaCyte-CB
• TABLE 7.3: Cord Blood Expansion Approaches in Ongoing Clinical Trials
• TABLE 8.1: Cord Blood Units Registered with WMDA Registry
• TABLE 8.2: Number of Unrelated CB Donors and CBUs available Worldwide
• TABLE 8.3: Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
• TABLE 9.1: Malignant Diseases Treated by UCB Transplantation
• TABLE 9.2: Non-Malignant Diseases Treated by UCB Transplantation
• TABLE 9.3: Diseases being studied using UCB as Regenerative Medicine
• TABLE 10.1: Numbers of CB, BM and PB Stem Cell Transplantations Compared by Year
• TABLE 10.2: Number of HCTs Performed in the U.S. by Disease as reported to CIBMTR
• TABLE 10.3: Number of HCTs Performed in the U.S. by Cell Source and Donor Type
• TABLE 10.4: Comparison of Median Costs during Transplant Admit
• TABLE 10.5: Complications Post HCT in UCB vs. MRD BM/PBSC vs. MURD BM/PBSC
• TABLE 11.1: Clinical Trials Evaluating the Effect of Cord Blood Stem Cells on Autism
• TABLE 11.2: Trials Evaluating the Effect of Cord Blood Stem Cells on Cerebral Palsy
• TABLE 11.3: Clinical Trials Studying the Effect of CBU on Alzheimer's Disease
• TABLE 11.4: Clinical Trials Evaluating the Effect of Cord Blood Stem Cells on Diabetes
• TABLE 11.5: Trials Evaluating the Effect of Cord Blood Stem Cells on Heart Diseases
• TABLE 11.6: Clinical Trials Evaluating the Effect of UCB on Multiple Sclerosis
• TABLE 11.7: Clinical Trials Evaluating the Effect of UCB on Stroke
• TABLE 12.1: Global Cord Blood Banking Service Market, 2022-2030
• TABLE 12.2: Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue, 2022-2030
• TABLE 13.1: Angiocrine's R&D Pipeline
• TABLE 13.2: Baylx's hUC-MSC-Derived Product Pipeline
• TABLE 13.3: Growth of Cord Blood Units in Be The Match Registry by Year
• TABLE 13.4: Diversity of CBUs in Be The Match Registry
• TABLE 13.5: Cell Care's Pricing for Cord Blood Processing and Storage
• TABLE 13.6: Cellenkos' Product Pipeline
• TABLE 13.7: Cord Blood Releases from Cells4Life
• TABLE 13.8: Celularity's Active Clinical Pipeline
• TABLE 13.9: Cord Blood Unitts Released from Cord Blood Center Group by Year
• TABLE 13.10: Cord Blood and Cord Tissue Units Released from CordLife
• TABLE 13.11: Recovery of Viable CFU by PrepaCyte-CB
• TABLE 13.12: Cryo-Cell International's Revenue Generation, 2017 to Present
• TABLE 13.13: Cryo-Cell International's Pricing
• TABLE 13.14: CryoCyte's Option Plans & Pricing
• TABLE 13.15: DKMS' Donor Typing Profile & Active Donors
• TABLE 13.16: Allogeneic and Autologous infusions by Indication Reported by EBMT
• TABLE 13.17: Cord Blood Banking Cost in GeneCell
• TABLE 13.18: GCBC's Revenue Generation, 2015 to Present
• TABLE 13.19: Glycostem's Product Pipeline
• TABLE 13.20: Insception LifeBank's Pricing
• TABLE 13.21: Cord Blood Releases from Insception LifeBank for Transplantation
• TABLE 13.22: Cord Blood Cells Released for Regenerative Medicine from Insception
• TABLE 13.23: Kangstem's Sponsor Initiated Clinical Trials
• TABLE 13.24: LifeCell International's Pricing
• TABLE 13.25: Maze Cord Blood: Banking Cost
• TABLE 13.26: MiracleCord's Cord Blood Banking Cost
• TABLE 13.27: MonoTx's Product Pipeline